KROS Company Profile and Key Details

Keros Therapeutics, Inc. (NASDAQ:KROS) closed at $10.41 USD, losing -$0.50 (-4.63%) from the previous close of $10.91. The stock is currently mid-range between its 52-week high and low $9.69 and $22.55. With a market capitalization of about $333.10 million, Keros Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.96). Key stats such as the average daily volume over the past year has been around 318.51 thousand shares, in line with its 52-week average. Headquartered in Lexington, MA, Keros Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jasbir S. Seehra, the company employs approximately 163 people and listed since April 08, 2020. Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options.

Short-term trend indicators are mixed aligned (SMA20 -10.92%, SMA50 -18.8%, SMA200 -6.63%). The stock’s 14-day RSI is 25.38 (weak momentum), while the ATR of 0.65 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.35% below its high and over 64.8% above its low. Average 10-day trading volume of 285.01 thousand shares is below the 3-month average of 319.35 thousand, indicating normal recent market interest.

Keros Therapeutics, Inc. has 40.62 million shares outstanding. The public float is 27.23 million shares, elevated short interest at 18.67% of float. This equals 4.84 million shares. The short ratio is 10.81 days. Institutional investors hold 103.46% of the float. Insiders own 2.73%. Seehra Jasbir holds 385.71 thousand shares, ORBIMED ADVISORS LLC has 119.52 thousand shares and GORDON CARL L has 119.52 thousand shares. Over the past six months, insider transactions show net selling. They sold 28.80 thousand shares across 8 transactions.

Keros Therapeutics, Inc. generated EPS of $1.54 over the past year. Five-year average earnings growth is -48.13%. Wall Street analysts project EPS growth of 5.51% annually over the next five years. The latest quarter delivered EPS of -$1.21. The next quarter is forecast at -$0.70. Next year's EPS is expected at -$3.63. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 1 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $16.00. The high target offers 159.37% upside. The low target suggests 53.7% downside. The mean target is $21.33. This offers 104.9% upside. Keros Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by 4.31%. The prior quarter beat by 75.51%. Over the last six quarters, Apple has recorded several small beats. These include -16.18% in February 26, 2025.

Keros Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $13.65. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Keros Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected fall of -78.0%, reaching $2.29 by September 22, 2026, with a range of $0.82 to $3.47. 1-Year Outlook: Projected loss of -26.22%, with price at $7.68 by June 25, 2027, within a range of $0.00 to $6.08.

Keros Therapeutics, Inc. (NASDAQ:KROS) shares are flat -9.48% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Keros Therapeutics, Inc. trading at a premium to the broader market with a P/E of -4.32. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $63.93, suggesting 514.12% upside.

Keros Therapeutics, Inc. trades at a P/E ratio of -4.32, slightly below the S&P 500 average, with a price-to-sales ratio of 10.16 and a price-to-book ratio of 1.37 suggesting the stock is closer to book value. The P/FCF stands at -5.79, also above market averages.